Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
Recombinant activated coagulation factor VII (rFVIIa) was developed initially for treatment of patients with hemophilia and neutralizing antibodies ("inhibitors") to coagulation factors VIII or IX. Owing to the unique and selective mechanism of action of rFVIIa and encouraged by clinical experience with other circumstances of inadequate hemostasis, a broad development program has been pursued to test potential efficacy and evaluate safety of this biologic for indications other than hemophilia. This review summarizes the current development of rFVIIa, focusing on results of prospective, randomized clinical trials.
Weiskopf
R B
RB
Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd, Denmark. rwes@novonordisk.com
D001778:Blood Coagulation Disorders / Q000188:drug therapy; D001930:Brain Injuries / Q000188:drug therapy; D002543:Cerebral Hemorrhage / Q000188:drug therapy; D005167:Factor VII / Q000627:therapeutic use*; D005168:Factor VII Deficiency / Q000188:drug therapy; D015942:Factor VIIa; D006467:Hemophilia A / Q000188:drug therapy; D006470:Hemorrhage / Q000188:drug therapy; D006801:Humans; D019106:Postoperative Hemorrhage / Q000188:drug therapy; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D012449:Safety; D013915:Thrombasthenia / Q000188:drug therapy; D014947:Wounds and Injuries / Q000188:drug therapy
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa